Herb Cross is to join KaloBios as the company’s new chief financial officer.
After a transition period, he will succeed Jeffrey Cooper sometime in October or November, when Cooper is set to retire to spend more time with his family.
Cross joins from biopharma company Affymax, where he was also chief financial officer.
David Pritchard, president and CEO of KaloBios, described Cross as a “well respected finance professional with over sixteen years of experience”.
“His prior work in monoclonal antibody companies and his broad leadership roles in public companies will be invaluable to KaloBios as we focus on our next stage of growth and development,” added Pritchard.
This growth is being led by three drug development programmes for therapies to treat respiratory disorders and cancer.
This includes KB001-A, which is being developed in partnership with Sanofi for the treatment of Pseudomonas aeruginosa (Pa) infections as well as by KalaBios alone as cystic fibrosis treatment.
Cross said: “KaloBios has an interesting and diverse pipeline of monoclonal antibody therapeutic candidates in clinical development, in important areas of unmet medical need.”